Publicaciones en colaboración con investigadores/as de KU Leuven (65)

2024

  1. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

  2. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx (Nature, (2023), 616, 7957, (525-533), 10.1038/s41586-023-05783-5)

    Nature

  3. Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy

    Radiotherapy and Oncology, Vol. 198

  4. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

  5. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

    Nature Communications, Vol. 15, Núm. 1

  6. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

    Frontiers in Oncology, Vol. 14

  7. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 7, pp. 1041-1050

  8. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

    Nature Communications , Vol. 15, Núm. 1

  9. SENECA study: staging endometrial cancer based on molecular classification

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321

  10. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

    Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284

  11. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

    Nature Cancer, Vol. 5, Núm. 2, pp. 347-363

  12. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

    New England Journal of Medicine, Vol. 391, Núm. 1, pp. 44-55

2023

  1. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

    Nature, Vol. 616, Núm. 7957, pp. 563-573

  2. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  3. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 833-845

  4. Genomic–transcriptomic evolution in lung cancer and metastasis

    Nature, Vol. 616, Núm. 7957, pp. 543-552

  5. Lung adenocarcinoma promotion by air pollutants

    Nature, Vol. 616, Núm. 7955, pp. 159-167

  6. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

    Gynecologic Oncology, Vol. 178, pp. 119-129

  7. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

    European Journal of Cancer, Vol. 188, pp. 131-139

  8. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 170, pp. 300-308